

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Cutia Therapeutics

科笛集团

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2487)

VOLUNTARY ANNOUNCEMENT

INCLUSION OF THE COMPANY IN FTSE GLOBAL EQUITY INDEX SERIES

This announcement is made by Cutia Therapeutics (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The board of directors (the “**Board**”) of the Company is pleased to announce that, the Company has been selected and included in the following FTSE Global Equity Index Series, with effect after the close of business on 15 March 2024:

1. FTSE Global Micro Cap Index; and
2. FTSE Global Total Cap Index.

The Board believes that the Company’s inclusion in the FTSE Global Equity Index Series represents international capital market recognition of the Group’s business performance and development prospects, and is expected to further facilitate the expansion of the Company’s shareholder base and increase trading liquidity of the shares of the Company. Meanwhile, the endorsement of the authoritative international index also helps to enhance the reputation and attention of the Group in the global capital markets.

The Board would like to thank the shareholders and investors of the Company for their continuous support. The Company will continue to actively seek market opportunities, strive to develop its business and create value for its shareholders.

By order of the Board
Cutia Therapeutics
Zhang Lele
Chief Executive Officer and Executive Director

Hong Kong, 18 March 2024

As at the date of this announcement, the Board comprises (i) Ms. Zhang Lele and Mr. Huang Yuqing as executive directors; (ii) Dr. Chen Lian Yong, Dr. Xie Qin, Dr. Huang Xiao and Ms. Yang Yunxia as non-executive directors; and (iii) Mr. Chung Ming Kit, Mr. Tao Tak Yan Dennis and Mr. Ye Xiaoxiang as independent non-executive directors.